Features

Commercial Infographic | Highlighting top healthcare trends

Infographic | Highlighting top healthcare trends

There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.

Agencies 10 myths about millennials and their healthcare habits

10 myths about millennials and their healthcare habits

More has been written about millennials — and their healthcare habits — than about any other generation. Here, Gen Y marketers explain why most of what you've read is wrong.

Corporate 2018 MAHF: Leverte 'was as good with clients as anyone you've ever seen'

2018 MAHF: Leverte 'was as good with clients as anyone you've ever seen'

Zero people have such tales about Robert Leverte, which is why news of his pending induction into the Medical Advertising Hall of Fame was received warmly when it was made public last October.

Features Big Predictions: Agency gurus on the future of data in the industry

Big Predictions: Agency gurus on the future of data in the industry

We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma marketing. Here's what they had to say.

Features High five: How these companies are leveraging data to engage A-list HCPs

High five: How these companies are leveraging data to engage A-list HCPs

In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.

Features Real-world evidence: It's finally having its moment

Real-world evidence: It's finally having its moment

Fueled by system-wide demand and facilitated by AI, the industry's lofty expectations around real-world evidence could soon be fulfilled

Features Cost over sight? Spark's blindness cure has the industry talking

Cost over sight? Spark's blindness cure has the industry talking

Spark has priced its cure for a rare form of blindness at $425,000 per eye. But rather than the science or the cost, pharma is buzzing over the company's outcomes-based pricing model

Features As CAR-Ts go from candidates to brands, what's the marketing strategy?

As CAR-Ts go from candidates to brands, what's the marketing strategy?

Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.

Features Get to know your data scientist: Four data aces share their knowledge

Get to know your data scientist: Four data aces share their knowledge

Four data aces share their backgrounds, inspirations, and guiding philosophies

Features Read the January 2018 Digital Edition

Read the January 2018 Digital Edition

Read the January 2018 issue in its entirety.